US 11,964,941 B2
5-Bromo-indirubins
Sangkil Nam, Tujunga, CA (US); David Horne, Altadena, CA (US); and Jun Xie, Duarte, CA (US)
Assigned to City of Hope, Duarte, CA (US)
Filed by City of Hope, Duarte, CA (US)
Filed on Jul. 6, 2020, as Appl. No. 16/921,856.
Application 16/921,856 is a continuation of application No. 15/893,488, filed on Feb. 9, 2018, granted, now 10,703,718.
Application 15/893,488 is a continuation of application No. 14/659,286, filed on Mar. 16, 2015, abandoned.
Claims priority of provisional application 61/953,169, filed on Mar. 14, 2014.
Prior Publication US 2021/0053919 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/40 (2006.01); A61K 31/404 (2006.01); C07D 209/34 (2006.01); C07D 403/04 (2006.01)
CPC C07D 209/40 (2013.01) 16 Claims
 
1. A method of treating acute myeloid leukemia expressing a FLT3-kinase in a subject in need thereof, said method comprising administering an effective amount of a compound having the formula:

OG Complex Work Unit Chemistry
wherein,
L is a substituted or unsubstituted alkylene;
R1 is —NR2R3;
R2 and R3 are independently substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, wherein R2 and R3 are optionally joined together to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and
R5 and R6 are independently hydrogen or halogen;
including pharmaceutically acceptable salts thereof,
thereby treating said acute myeloid leukemia.